Emergent BioSolutions announced that its investigational anthrax vaccine, NuThrax (anthrax vaccine adsorbed with CPF 7909 adjuvant) has been granted fast track designation by the FDA. NuThrax is currently being studied in a Phase 1b clinical trial for safety, tolerability, and immunogenicity.
NuThrax consists of BioThrax (anthrax vaccine adsorbed) and a novel immunostimulatory oligodeoxynucleotide compound, CPG 7909.

For more information call (301) 795-1800 or visit www.emergentbiosolutions.com.